Status:
ACTIVE_NOT_RECRUITING
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Adrenocortical Carcinoma
Eligibility:
All Genders
Brief Summary
Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis...
Detailed Description
Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients enrolled on any of the studies listed below:
- 92-C-0268, 93-C-0200, 00-C-0044, 01-C-0129, 04-C-001, 09-C-0242, 08-C-0176, 10-C-0203, 13-C-0114, 14-C-0029
- EXCLUSION CRITERIA:
- Patients who opted out of future use of data on their prior studies will be excluded from this study.
Exclusion
Key Trial Info
Start Date :
April 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04358107
Start Date
April 20 2020
End Date
December 31 2026
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892